Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Tenax Therapeutics, Inc.

Market Cap 632M 546M 503M 471M 882M 60.05B 896M 5.94B 2.31B 29.23B 2.37B 2.32B 101B P/E Ratio 2026 *
-7.09x
P/E Ratio 2027 * -7.6x
Enterprise Value 632M 546M 503M 471M 882M 60.05B 896M 5.94B 2.31B 29.23B 2.37B 2.32B 101B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.88%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day+7.22%
1 week+7.92%
Current month-2.44%
1 month-4.85%
3 months-18.39%
6 months+11.67%
Current year-5.00%
1 week 10.25
Extreme 10.25
12.3
1 month 10.25
Extreme 10.25
12.75
Current year 10.25
Extreme 10.25
18.38
1 year 5.34
Extreme 5.34
18.38
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,680
10 years 2.77
Extreme 2.77
88,960
Manager TitleAgeSince
Chief Executive Officer 52 2021-07-13
Director of Finance/CFO 58 2026-05-10
Chief Tech/Sci/R&D Officer - 2025-01-20
Director TitleAgeSince
Chairman 67 2021-05-31
Director/Board Member 76 2021-02-24
Director/Board Member 68 2021-02-24
Date Insider Type Main position Quantity % Market Cap.
05-10Other

Chief Financial Officer

0 0%
05-10Free

Chief Financial Officer

460,000 2.6748%
01-29Other

Controller/Auditor

50,000 0.8008%
Change 5-day change 1-year change 3-year change Capi.($)
+7.22%+7.92%+97.95%-56.66% 632M
-0.35%+0.97%-15.96%-12.73% 42.96B
+3.16%+2.88%+273.46%+506.60% 31.73B
-0.74%-2.20%+12.75%-15.33% 30.22B
+1.74%-1.98%-4.25%+24.19% 28.94B
+4.09%-1.98%+11.99%+17.37% 23.87B
-1.42%+3.56%+54.74%+115.77% 13.57B
-0.40%-1.29%+6.06%+7.59% 12.96B
+2.63%+5.01% - - 13.39B
-0.48%-1.53%+105.90%+76.17% 12.2B
Average +1.52%-0.96%+60.29%+73.66% 21.05B
Weighted average by Cap. +1.00%-1.09%+54.37%+95.09%

Financials

2026 *2027 *
Net sales - -
Net income -81.07M -70.02M -64.53M -60.4M -113M -7.71B -115M -762M -297M -3.75B -304M -298M -12.99B -94.93M -81.99M -75.56M -70.73M -133M -9.02B -135M -892M -348M -4.39B -356M -349M -15.21B
Net Debt - -
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
26-06-12 11.60 $ +8.11% 1,283,502
26-06-11 10.73 $ +1.71% 948,697
26-06-10 10.55 $ -1.68% 381,349
26-06-09 10.73 $ +1.80% 1,445,841
26-06-08 10.54 $ -1.77% 588,076
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.73USD
Average target price
34.00USD
Spread / Average Target
+216.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!